A Phase IV Study Comparing Oral Dolasetron (Anzemet) to Oral Granisetron (Kytril) for Acute Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

Grants and Contracts Details

StatusFinished
Effective start/end date7/15/027/15/04

Funding

  • Aventis Pharmaceuticals Products Inc: $69,363.00